Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical ...

Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the ...

Shares of Merck & Co. Inc. MRK were unchanged Tuesday, on what proved to be an all-around dismal trading session for the ...

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...

Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in ...

U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and ...

Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company.

(RTTNews) - Merck & Co., Inc. (MRK), Wednesday announced that the company has entered into an exclusive global license deal with China-based Hansoh Pharma to develop, manufacture and commercialize ...

Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and ...

U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and ...

Merck (NYSE:MRK) and Chinese biopharmaceutical company Hansoh Pharma (OTCPK:HNSPF) announced a global licensing deal on ...